Celltrion said Tuesday that its largest-ever cancellation of treasury shares has been fully reflected in the stock market following a change listing on April 13.
With the process complete, the company said its total number of outstanding shares fell by about 4%. Celltrion described the move as the largest treasury-share cancellation ever in South Korea’s pharmaceutical and biotech industry.
The canceled shares accounted for about 74% of the company’s treasury stock and 3.94% of total issued shares. Based on the previous day’s closing price, the cancellation was valued at about 1.7782 trillion won, exceeding the combined size of its treasury-share cancellations in 2024 and 2025. Celltrion said the cancellation is expected to improve earnings per share.
Earlier, Celltrion said it recorded a shareholder return rate of about 103% last year through a cash dividend of 750 won per share and treasury-share cancellations, surpassing its stated three-year average target of 40%.
A Celltrion official said the cancellation was aimed at boosting shareholder value and expressed confidence it would be a turning point for the company to be properly valued alongside future earnings growth.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.